Therefore, it is expected that targeting TNF-α/TNFR signaling and downstream NF-κB molecules activation through CME should improve ovarian cancer cell sensitivity to platinum based chemotherapy. The gene discussed is TNFRSF1A; the disease is ovarian carcinoma.